Skip to main content

news

 

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.

Kirkland & Ellis offered legal advice to the financial advisor, China International Capital Corporation (CICC), in the deal.

Henlius, established in 2010, was listed in Hong Kong in September 2019. Its product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China and has three products approved for international markets. In 2023, the company achieved its first annual profit.

The Freshfields team was led by partners Edward Freeman, Grace Huang, and David Yi.

The Kirkland team was led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Cleary, A&O Shearman advise on Goodyear's $701 mln Dunlop sale

by Asian Legal Business《亚洲法律杂志》 |

Cleary Gottlieb has advised tyremaker Goodyear Tire & Rubber Company on the $701 million sale of its Dunlop brand to Japan's Sumitomo Rubber Industries (SRI), which was represented by A&O Shearman.

Deals

Mori Hamada, Nagashima Ohno advise on $1.6 bln bid for Fujitsu General

by Asian Legal Business《亚洲法律杂志》 |

Japanese law firms Mori Hamada & Matsumoto and Nagashima Ohno & Tsunematsu are playing key roles in Paloma Rheem Holdings' 257 billion yen ($1.6 billion) offer to acquire air conditioner manufacturer Fujitsu General.

Deals

CAM, Khaitan, Linklaters act on $355 mln Sai Life Sciences IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has driven the $355 million initial public offering of TPG-backed Indian healthcare R&D firm Sai Life Sciences, with Khaitan & Co and Linklaters advising the bookrunning lead managers. CAM has also acted for selling promoter shareholders Sai Quest Syn.